'Groundbreaking' New Drug Gives Hope in Huntington's Disease

Scientists have for the first time fixed a protein defect that causes Huntington's disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease. The success in the early-stage clinical trial has prompted Roche to exercise its option to license the product, called IONIS-HTT(Rx), at a cost of $45 million. Lead researcher Sarah Tabrizi, professor of clinical neurology at University College London, said the ability...

What feeling does this article give you?

#hashtags to follow:

Huntington [+]    Ionis Pharmaceuticals [+]    Roche [+]    IONIS [+]    HTT [+]    Sarah Tabrizi [+]    University College London [+]   

More #news: